Objective To provide the first international comparison of oesophageal and gastric cancer survival by stage at diagnosis and histological subtype across high-income countries with similar access to healthcare. Methods As part of the ICBP SURVMARK-2 project, data from 28 923 patients with oesophageal cancer and 25 946 patients with gastric cancer diagnosed during 2012–2014 from 14 cancer registries in seven countries (Australia, Canada, Denmark, Ireland, New Zealand, Norway and the UK) were included. 1-year and 3-year age-standardised net survival were estimated by stage at diagnosis, histological subtype (oesophageal adenocarcinoma (OAC) and oesophageal squamous cell carcinoma (OSCC)) and country. Results Oesophageal cancer survival was highest in Ireland and lowest in Canada at 1 (50.3% vs 41.3%, respectively) and 3 years (27.0% vs 19.2%) postdiagnosis. Survival from gastric cancer was highest in Australia and lowest in the UK, for both 1-year (55.2% vs 44.8%, respectively) and 3-year survival (33.7% vs 22.3%). Most patients with oesophageal and gastric cancer had regional or distant disease, with proportions ranging between 56% and 90% across countries. Stage-specific analyses showed that variation between countries was greatest for localised disease, where survival ranged between 66.6% in Australia and 83.2% in the UK for oesophageal cancer and between 75.5% in Australia and 94.3% in New Zealand for gastric cancer at 1-year postdiagnosis. While survival for OAC was generally higher than that for OSCC, disparities across countries were similar for both histological subtypes. Conclusion Survival from oesophageal and gastric cancer varies across high-income countries including within stage groups, particularly for localised disease. Disparities can partly be explained by earlier diagnosis resulting in more favourable stage distributions, and distributions of histological subtypes of oesophageal cancer across countries. Yet, differences in treatment, and also in cancer registration practice and the use of different staging methods and systems, across countries may have impacted the comparisons. While primary prevention remains key, advancements in early detection research are promising and will likely allow for additional risk stratification and survival improvements in the future. No data are available.

中文翻译：

---

2012-2014 年食管癌和胃癌生存率的国际差异：组织学亚型和诊断分期的差异（ICBP SURVMARK-2 基于人群的研究）


目的 首次对具有相似医疗保健条件的高收入国家的食管癌和胃癌的诊断阶段和组织学亚型生存情况进行国际比较。方法 作为 ICBP SURVMARK-2 项目的一部分，数据来自 2012 年至 2014 年期间来自 7 个国家（澳大利亚、加拿大、丹麦、爱尔兰、新西兰、挪威和英国）也包括在内。按诊断时的分期、组织学亚型（食管腺癌 (OAC) 和食管鳞状细胞癌 (OSCC)）和国家/地区估算 1 年和 3 年年龄标准化净生存率。结果 诊断后 1 年（分别为 50.3% vs 41.3%）和 3 年（27.0% vs 19.2%）食管癌生存率在爱尔兰最高，在加拿大最低。胃癌的 1 年生存率（分别为 55.2% vs 44.8%）和 3 年生存率（33.7% vs 22.3%）在澳大利亚最高，在英国最低。大多数食管癌和胃癌患者患有局部或远处疾病，各国比例在 56% 至 90% 之间。阶段特异性分析显示，局部疾病的国家间差异最大，1-1 年间，食管癌的生存率在澳大利亚为 66.6%，在英国为 83.2%，在澳大利亚为 75.5%，在新西兰为 94.3%。诊断后一年。虽然 OAC 的生存率普遍高于 OSCC，但两种组织学亚型的国家间差异相似。结论 在高收入国家，食管癌和胃癌的生存率存在差异，包括在分期组内，尤其是局部疾病。 差异的部分原因是早期诊断导致更有利的分期分布以及各国食管癌组织学亚型的分布。然而，各国治疗、癌症登记实践以及不同分期方法和系统使用的差异可能会影响比较。虽然一级预防仍然是关键，但早期检测研究的进展是有希望的，并且可能会在未来实现额外的风险分层和生存改善。无可用数据。